Tag
Preoperative neutrophil-to-lymphocyte ratio (NLR) predicts poor outcomes in high-risk cutaneous squamous cell carcinoma, offering a cost-effective tool to enhance risk stratification.
The COMPASS-SCC, developed from a large international cohort, offers improved prognostic accuracy for cutaneous squamous cell carcinoma compared to existing AJCC8 and BWH staging systems, aiding clinical decision-making for metastasis and m
The integrated 40-gene expression profile (i40-GEP) improves risk stratification in high-risk cutaneous squamous cell carcinoma, accurately predicting metastasis and local recurrence, and identifying patients who benefit most from adjuvant
A multidisciplinary Delphi panel offers practical, consensus-based recommendations to standardize when and how to use staging and surveillance imaging for localized cutaneous squamous cell carcinoma (CSCC).
The Dutch Keratinocyte Cancer Collaborative (DKCC) provides the first nationwide longitudinal real-world dataset of advanced cutaneous squamous cell carcinoma (CSCC), estimating that 8% of CSCC are locally advanced and demonstrating short m
The randomized MATISSE trial shows neoadjuvant nivolumab ± low‑dose ipilimumab yields high major/partial pathological response rates, excellent 2‑year disease‑specific survival, and enables organ preservation in many patients with resectabl
A meta-analysis of over 320,000 participants confirms that painful, blistering sunburns, especially in childhood, significantly increase the risk of cutaneous squamous cell carcinoma (cSCC).
Adjuvant cemiplimab significantly improves disease-free survival in patients with high-risk cutaneous squamous-cell carcinoma post-surgery and radiotherapy, reducing locoregional and distant recurrences compared to placebo, with manageable
